Morcos-Sandino Michelle, Quezada-Ramírez Sofia Isabel, Gómez-De León Andrés
Hematology Service, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León (UANL), Av. Madero y Gonzalitos S/N, Mitras Centro, Monterrey ZC 64460, Nuevo León, Mexico.
Biomedicines. 2025 May 18;13(5):1221. doi: 10.3390/biomedicines13051221.
Acute myeloid leukemia (AML) presents a significant global health challenge due to its aggressive behavior and mortality rates. Traditionally, AML treatment has relied on intensive chemotherapy-anthracyclines and cytarabine. However, recent breakthroughs in targeted therapies are transforming clinical practices. This review examines current treatment strategies, including breakthrough therapies. Also, a global perspective on AML management includes the disparity in treatment availability, particularly the difficulties faced by low- and middle-income countries due to the high cost and restricted access to novel therapies.
急性髓系白血病（AML）因其侵袭性和死亡率给全球健康带来了重大挑战。传统上，AML的治疗依赖于强化化疗——蒽环类药物和阿糖胞苷。然而，靶向治疗的最新突破正在改变临床实践。本综述探讨了当前的治疗策略，包括突破性疗法。此外，对AML管理的全球视角包括治疗可及性的差异，特别是低收入和中等收入国家由于高成本和新型疗法获取受限所面临的困难。
